HOME > ARCHIVE

ARCHIVE

Semi-annual Business Results

December 6, 2004
Top 28 Post 0.1% Decline in Non-consolidated Sales

December 6, 2004
VITAL-NET: Profits Down Sharply Despite Growth in Sales

December 6, 2004
Japan Should Boost Healthcare Spending to 9% of GDP: Mr Butler of PhRMA

December 6, 2004
SSP: Sales of Rx Drugs Up 6.1% to \5.8 Bil.

December 6, 2004
NEW PRODUCTS

December 6, 2004
SSP to Concentrate on Consumer Healthcare: VP Yamashita

December 6, 2004
Wyeth's Enbrel Receives Import Approval

December 6, 2004
Semi-annual Business Results

November 29, 2004
Semi-annual Business Results

November 29, 2004
Semi-annual Business Results

November 29, 2004
Semi-annual Business Results

November 29, 2004
Semi-annual Business Results

November 29, 2004
OTC NEWS IN BRIEF

November 29, 2004
Increased Demand Brings Good Performances to CMIC

November 29, 2004
RESEARCH & DEVELOPMENT NEWS IN BRIEF

November 29, 2004
Cancer Treatment GLs in Preparation: JSCO

November 29, 2004
NEW PRODUCTS

November 29, 2004
MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

November 29, 2004
REGULATORY NEWS IN BRIEF

November 29, 2004

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…